None of the other patients received specific guideline-directed medical therapy for heart failure, such as ACE inhibitors, beta-blockers, or mineralocorticoid receptor antagonists, as recommended in the 2022 ESC cardio-oncology guidelines. This evidence concerns the gene NR3C2 and heart failure.